These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25590604)

  • 1. Validation of a multiprotein plasma classifier to identify benign lung nodules.
    Vachani A; Pass HI; Rom WN; Midthun DE; Edell ES; Laviolette M; Li XJ; Fong PY; Hunsucker SW; Hayward C; Mazzone PJ; Madtes DK; Miller YE; Walker MG; Shi J; Kearney P; Fang KC; Massion PP
    J Thorac Oncol; 2015 Apr; 10(4):629-37. PubMed ID: 25590604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
    Silvestri GA; Tanner NT; Kearney P; Vachani A; Massion PP; Porter A; Springmeyer SC; Fang KC; Midthun D; Mazzone PJ;
    Chest; 2018 Sep; 154(3):491-500. PubMed ID: 29496499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Kossenkov AV; Qureshi R; Dawany NB; Wickramasinghe J; Liu Q; Majumdar RS; Chang C; Widura S; Kumar T; Horng WH; Konnisto E; Criner G; Tsay JJ; Pass H; Yendamuri S; Vachani A; Bauer T; Nam B; Rom WN; Showe MK; Showe LC
    Cancer Res; 2019 Jan; 79(1):263-273. PubMed ID: 30487137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.
    Li XJ; Hayward C; Fong PY; Dominguez M; Hunsucker SW; Lee LW; McLean M; Law S; Butler H; Schirm M; Gingras O; Lamontagne J; Allard R; Chelsky D; Price ND; Lam S; Massion PP; Pass H; Rom WN; Vachani A; Fang KC; Hood L; Kearney P
    Sci Transl Med; 2013 Oct; 5(207):207ra142. PubMed ID: 24132637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Establishment and Verification of A Novel Predictive Model of Malignancy
for Non-solid Pulmonary Nodules].
    Xiao F; Yu Q; Zhang Z; Liu D; Liang C
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):26-33. PubMed ID: 30674390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.
    Vachani A; Hammoud Z; Springmeyer S; Cohen N; Nguyen D; Williamson C; Starnes S; Hunsucker S; Law S; Li XJ; Porter A; Kearney P
    Lung; 2015 Dec; 193(6):1023-7. PubMed ID: 26376647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of conventional tumor markers in young patients with pulmonary nodules.
    Xu L; Su Z; Xie B
    J Clin Lab Anal; 2021 Sep; 35(9):e23912. PubMed ID: 34296781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
    BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
    Schotten LM; Darwiche K; Seweryn M; Yildiz V; Kneuertz PJ; Eberhardt WEE; Eisenmann S; Welter S; Sisson BE; Pietrzak M; Wiesweg M; Ploenes T; Hager T; He K; Freitag L; Aigner C; Taube C; Oezkan F
    Eur J Cancer; 2021 Apr; 147():142-150. PubMed ID: 33662689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.
    Jung YJ; Katilius E; Ostroff RM; Kim Y; Seok M; Lee S; Jang S; Kim WS; Choi CM
    Clin Lung Cancer; 2017 Mar; 18(2):e99-e107. PubMed ID: 27836219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules.
    Liu QX; Zhou D; Han TC; Lu X; Hou B; Li MY; Yang GX; Li QY; Pei ZH; Hong YY; Zhang YX; Chen WZ; Zheng H; He J; Dai JG
    Adv Sci (Weinh); 2021 Jul; 8(13):2100104. PubMed ID: 34258160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.
    Lin Y; Leng Q; Jiang Z; Guarnera MA; Zhou Y; Chen X; Wang H; Zhou W; Cai L; Fang H; Li J; Jin H; Wang L; Yi S; Lu W; Evers D; Fowle CB; Su Y; Jiang F
    Int J Cancer; 2017 Sep; 141(6):1240-1248. PubMed ID: 28580707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
    Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J
    J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
    Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
    Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Integrated Classifier's Ability to Distinguish Benign From Malignant Lung Nodules: Extended Analyses and 2-Year Follow-Up Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
    Tanner NT; Springmeyer SC; Porter A; Jett JR; Mazzone P; Vachani A; Silvestri GA
    Chest; 2021 Mar; 159(3):1283-1287. PubMed ID: 33171158
    [No Abstract]   [Full Text] [Related]  

  • 19. Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study.
    Li Y; Xie F; Zheng Q; Zhang Y; Li W; Xu M; He Q; Li Y; Sun J
    Lung Cancer; 2024 Sep; 195():107930. PubMed ID: 39146624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer-aided diagnosis of lung cancer: the effect of training data sets on classification accuracy of lung nodules.
    Gong J; Liu JY; Sun XW; Zheng B; Nie SD
    Phys Med Biol; 2018 Feb; 63(3):035036. PubMed ID: 29311420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.